Raj Nagaraja

1.2k total citations
11 papers, 119 citations indexed

About

Raj Nagaraja is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Raj Nagaraja has authored 11 papers receiving a total of 119 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Genetics and 5 papers in Cancer Research. Recurrent topics in Raj Nagaraja's work include Glioma Diagnosis and Treatment (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Raj Nagaraja is often cited by papers focused on Glioma Diagnosis and Treatment (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Raj Nagaraja collaborates with scholars based in United States, Australia and France. Raj Nagaraja's co-authors include Rohini Narayanaswamy, Brandon Nicolay, Katharine Yen, Lee Silverman, Yuko Ishii, Andrew Olaharski, Guowen Liu, Janeta Popovici-Müller, Derek A. Cogan and Rachel M. Cole and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Toxicology and Applied Pharmacology.

In The Last Decade

Raj Nagaraja

9 papers receiving 117 citations

Peers

Countries citing papers authored by Raj Nagaraja

Since Specialization

Citations

This map shows the geographic impact of Raj Nagaraja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raj Nagaraja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raj Nagaraja more than expected).

Fields of papers citing papers by Raj Nagaraja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raj Nagaraja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raj Nagaraja. The network helps show where Raj Nagaraja may publish in the future.

Co-authorship network of co-authors of Raj Nagaraja

This figure shows the co-authorship network connecting the top 25 collaborators of Raj Nagaraja. A scholar is included among the top collaborators of Raj Nagaraja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raj Nagaraja. Raj Nagaraja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Abstract 1659: ETX-636, a novel allosteric pan-mutant-selective PI3Kα dual inhibitor and degrader with best-in-class potential 2025 ·Cancer Research ·Robert F. Koncar, (unknown), Jingyan Gao, Fei Pang, Ying Lin, Raj Nagaraja, Yong Tang, (unknown), (unknown), Karan Kapoor, (unknown), Eric Simone, Ming‐Hong Hao, Shengfang Jin, Tao Liu, Meghana Kulkarni, Jeffery L. Kutok	0
2	Abstract P4-12-29: ETX-197/BG-68501, a potential best-in-class potent, selective, oral, small molecule CDK2 inhibitor, has anti-tumor activity in cancer models with Cyclin E amplification or deficiency in the Retinoblastoma 1 gene 2025 ·Clinical Cancer Research ·Daliya Banerjee, (unknown), Jingyan Gao, Fei Pang, (unknown), Raj Nagaraja, Yong Tang, Zhipeng Fan, (unknown), Ming‐Hong Hao, Shengfang Jin, Tao Liu, Tai‐Tong Wong	0
3	Preclinical toxicology profile of squalene epoxidase inhibitors 2020 ·Toxicology and Applied Pharmacology ·Raj Nagaraja, Andrew Olaharski, Rohini Narayanaswamy, Christopher E. Mahoney, David Pirman, Stefan Größ, Thomas P. Roddy, Janeta Popovici-Müller, Gromoslaw A. Smolen, Lee Silverman	17
4	Abstract 3090: The MAT2A inhibitor, AG-270, combines with both taxanes and gemcitabine to yield enhanced anti-tumor activity in patient-derived xenograft models 2020 ·Cancer Research ·Marc L. Hyer, Peter Kalev, Mark P. Fletcher, (unknown), Elia Aguado-Fraile, Everton Mandley, (unknown), (unknown), Raj Nagaraja, (unknown), (unknown), Kevin M. Marks, Katya Marjon	3
5	Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·Bin Fan, David L. Dai, Marvin B. Cohen, Huansheng Xu, Feng Yin, Raj Nagaraja, (unknown), Caroline Almon, Frank G. Basile, Hua Yang	4
6	Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies 2018 ·Molecular Cancer Therapeutics ·Katharine Yen, Zenon Konteatis, Zhihua Sui, Erin Artin, Lenny Dang, Kimberly Straley, Erica R. Tobin, Carl Campos, Hua Yang, Raj Nagaraja, Yue Chen, Hyeryun Kim, Camelia Gliser, Brandon Nicolay, Andrew Olaharski, Lee Silverman, Scott A. Biller, Shinsan M. Su, Ingo K. Mellinghoff, Janeta Popovici-Müller	16
7	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML 2017 ·Leukemia ·Lev M. Kats, Stephin J. Vervoort, Rachel M. Cole, (unknown), Gareth P. Gregory, Eva Vidacs, Jason Li, Raj Nagaraja, Katharine Yen, Ricky W. Johnstone	23
8	EXTH-59. THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO 2017 ·Neuro-Oncology ·Brandon Nicolay, Rohini Narayanaswamy, (unknown), Raj Nagaraja, (unknown), Guowen Liu, Yuko Ishii	15
9	EXTH-34. COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO 2017 ·Neuro-Oncology ·Brandon Nicolay, Rohini Narayanaswamy, Michael Amatangelo, (unknown), Raj Nagaraja, (unknown), Guowen Liu, Yuko Ishii	8
10	Exploration of cathepsin S inhibitors characterized by a triazole P1–P2 amide replacement 2012 ·Bioorganic & Medicinal Chemistry Letters ·Neil Moss, Zhaoming Xiong, (unknown), Derek A. Cogan, (unknown), (unknown), (unknown), Eugene R. Hickey, Raj Nagaraja, Matthew R. Netherton, (unknown), (unknown), (unknown), Daw-Tsun Shih, Yancey D. Ward, Erick R. R. Young, Qing Zhang	11
11	A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties 2009 ·Bioorganic & Medicinal Chemistry Letters ·Neil Moss, Younggi Choi, Derek A. Cogan, Adam Flegg, (unknown), (unknown), (unknown), Raj Nagaraja, (unknown), (unknown), Janet T. Peterson, (unknown), Christopher R. Sarko, Donna Skow, (unknown), Heather Tye, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact